

ARTICLE OPEN



Heterogeneity of prodromal Parkinson symptoms in siblings of Parkinson disease patients

Luca Baldelli¹, Sebastian Schade^{2,3}, Silvia Jesús^{4,5}, Sebastian R. Schreglmann⁶, Luisa Sambati^{1,7}, Pilar Gómez-Garre^{4,5}, Claire Halsband^{2,3}, Giovanna Calandra-Buonaura^{1,7}, Astrid Daniela Adarmes-Gómez^{4,5}, Friederike Sixel-Döring^{8,9}, Corrado Zenesini⁷, Chiara Pirazzini⁷, Paolo Garagnani¹⁰, Maria Giulia Bacalini⁷, Kailash P. Bhatia⁶, Pietro Cortelli^{1,7}, Brit Mollenhauer^{8,11}, Claudio Franceschi⁷, PROPAG-AGEING consortium*, Pablo Mir^{4,5}, Claudia Trenkwalder^{3,8} and Federica Provini^{1,7}✉

A prodromal phase of Parkinson's disease (PD) may precede motor manifestations by decades. PD patients' siblings are at higher risk for PD, but the prevalence and distribution of prodromal symptoms are unknown. The study objectives were (1) to assess motor and non-motor features estimating prodromal PD probability in PD siblings recruited within the European PROPAG-AGEING project; (2) to compare motor and non-motor symptoms to the well-established DeNoPa cohort. 340 PD siblings from three sites (Bologna, Seville, Kassel/Goettingen) underwent clinical and neurological evaluations of PD markers. The German part of the cohort was compared with German de novo PD patients (dnPDs) and healthy controls (CTRs) from DeNoPa. Fifteen (4.4%) siblings presented with subtle signs of motor impairment, with MDS-UPDRS-III scores not clinically different from CTRs. Symptoms of orthostatic hypotension were present in 47 siblings (13.8%), no different to CTRs ($p = 0.072$). No differences were found for olfaction and overall cognition; German-siblings performed worse than CTRs in visuospatial-executive and language tasks. 3/147 siblings had video-polysomnography-confirmed REM sleep behavior disorder (RBD), none was positive on the RBD Screening Questionnaire. 173/300 siblings had <1% probability of having prodromal PD; 100 between 1 and 10%, 26 siblings between 10 and 80%, one fulfilled the criteria for prodromal PD. According to the current analysis, we cannot confirm the increased risk of PD siblings for prodromal PD. Siblings showed a heterogeneous distribution of prodromal PD markers and probability. Additional parameters, including strong disease markers, should be investigated to verify if these results depend on validity and sensitivity of prodromal PD criteria, or if siblings' risk is not elevated.

npj Parkinson's Disease (2021)7:78; <https://doi.org/10.1038/s41531-021-00219-1>

INTRODUCTION

Parkinson's disease (PD) is the second most frequent neurodegenerative disease with a prevalence of 50–300 per 100,000 for all ages, the incidence ranges from 10 to 30 per 100,000 person-years in western countries¹. Both prevalence and incidence increase nearly exponentially with age and peak at 6% after the age of 80^{2,3}. Risk factors for PD neurodegeneration lie in the various and complicated interplay between genetics and the environment, both of which contribute to the intrinsic heterogeneous nature of the disease⁴. The contribution of genetics to PD risk is currently estimated at around 30%, explained by a few monogenic⁵, but mainly polygenic mechanisms⁶. Age is the greatest non-familial risk factor⁷.

A prodromal phase of PD, characterized by a variety of non-motor symptoms (NMS), may precede the motor manifestation of the disease by years or even decades. When rapid eye movement sleep behavior disorder (RBD) occurs, the brainstem including subcoeruleus and reticularis magnocellularis nuclei and the limbic system are already affected. Olfactory dysfunction, cognitive impairment, autonomic dysfunction, pain, or fatigue may be already present at early stages^{8–10}, and can precede PD motor onset^{11–13} in the so-called PD prodromal phase^{14,15}. NMS are

present in the elderly general population as well, but a combination of two or more NMS increases the risk of developing PD, especially if combined with subtle motor impairment^{16–18}. Apart from idiopathic RBD, which has been widely studied as a specific marker for PD and alpha-synucleinopathies¹⁴, constipation and hyposmia make up the highest risk (up to 3.4 and 5.2-fold, respectively)^{14,19–22}, though being non-specific and common in the general elderly population^{23–25}. Although these markers are still not widely used in clinical practice and show a heterogeneous presentation in prodromal patients, the high conversion rate from the premotor or prodromal phase of the disease to PD provides a unique opportunity to directly observe disease development²⁶. Applying the Movement Disorders Society criteria for prodromal PD, which obtained a 98.8% specificity in a 10-year longitudinal study¹⁷, prodromal PD prevalence has been estimated around 2.4% in the general elderly population²⁷.

As mentioned above, family history is associated with an increased risk of PD development²⁸. A meta-analysis on epidemiological, referral, and registry-based studies showed a 2.9-fold increased risk in first-degree relatives of PD patients and a 4.4-fold increased risk of PD development in PD siblings^{29–32}. Some studies have specifically evaluated prodromal markers in

¹Department of Biomedical and NeuroMotor Sciences (DiBiNeM), University of Bologna, Bologna, Italy. ²Department of Clinical Neurophysiology, University Medical Center Göttingen, Göttingen, Germany. ³Department of Neurosurgery, University Medical Center Göttingen, Göttingen, Germany. ⁴Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain. ⁵Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Seville, Spain. ⁶University College London (UCL), Institute of Neurology, London, United Kingdom. ⁷IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy. ⁸Paracelsus-Elena-Klinik Kassel, Kassel, Germany. ⁹Neurologische Klinik, Philipps-University, Marburg, Germany. ¹⁰Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy. ¹¹Department of Neurology, University Medical Center Göttingen, Göttingen, Germany. *A list of authors and their affiliations appears at the end of the paper. ✉email: federica.provini@unibo.it

these individuals^{9,33,34}. More recently, PD first-degree relatives (siblings) were specifically found more likely to suffer from anxiety, depression, and clinically diagnosed RBD than controls³³. However, data are limited and the exact prevalence of prodromal PD signs and symptoms in PD siblings, and how they progress, are currently unknown.

The present work aims to comprehensively assess motor and NMS in PD siblings, to potentially define a high-risk group for developing PD for future interventions. We, therefore, considered a cross-sectional multi-center group of PD siblings (Sibs) recruited within the framework of the European PROPAG-AGEING (PPG) project. Within PPG, PD siblings, who have not been diagnosed with a neurodegenerative disease and do not fulfill the definition criteria of PD, are recruited in order to validate candidate clinical and biological (genetic, epigenetic, transcriptional, metabolic, lipid, and/or glycan) PD markers, as extensively described in Pirazzini et al.³⁵.

We aimed to describe the presence, distribution, and combination of motor and NMS in PD siblings and estimate their prodromal PD probability, and to compare the presented motor and NMS to the well-established longitudinal DeNoPa cohort³⁶.

RESULTS

Demographic and general clinical data

A total of 340 siblings ($n = 141$; 41.5% males) were included in the study from the three recruiting centers, their mean age was 62.13 ± 10.72 ; SAS siblings (Spanish Sibs) were the youngest aged 57.77 ± 11.17 years ($p < 0.001$). Four Sibs had two siblings affected with PD. Alcohol and coffee consumption were more frequent among German Sibs (57.7% and 88.2%, respectively), while Spanish Sibs had the highest per capita alcohol daily dose (20.51 ± 20.92 g/day; $p < 0.001$). Regarding comorbidities, hypothyroidism was more prevalent among German Sibs (19.2%; $p < 0.001$).

In order to exclude national clusterization, we compared the 120 German siblings with 159 unrelated German de novo PD patients (dnPDs) and 109 controls (CTRs), who showed a uniform mean age ($p = 0.875$). In comparison to dnPDs and CTRs, more German Sibs were men (46% vs 38.6%; $p < 0.001$), had higher education, and were more active smokers ($p < 0.001$). DeNoPa PDs presented with a higher BMI than German Sibs ($p = 0.001$). CTRs presented with the highest prevalence of dyslipidemia and the lowest of hyperuricemia (CTRs vs German Sibs: $p < 0.001$ and 0.048, respectively).

Demographic data and comorbidities are shown in Table 1; consumptions and medications intake can be found in Supplementary Table 1, blood test data in Supplementary Table 2.

Motor evaluation and impact on daily living

Sibs obtained a median motor score of 0 (0–2) on the MDS-UPDRS part III. Fifteen (4.4%) Sibs presented with subtle signs of motor impairment (MDS-UPDRS part III score without action and postural tremor > 6). German Sibs showed higher MDS-UPDRS III scores and reported a higher impact of motor symptoms on activities of daily living (MDS-UPDRS part II) than Italian and Spanish Sibs, even when adjusted for confounders.

Compared to CTRs, German Sibs presented with increased signs of motor impairment on the MDS-UPDRS part III ($p < 0.001$), 12 (10.0%) of them obtained a score greater than 6. German Sibs also presented with increased MDS-UPDRS part II scores than CTRs ($p < 0.001$).

Complete data on motor evaluation and motor impact on daily living are shown in Table 2.

Table 1. Demographic data and comorbidities of Siblings and DeNoPa cohorts.

	PROPAG-AGEING Siblings' cohort				DeNoPa cohort		Siblings' comparisons		Comparisons with DeNoPa	
	Total Sibs ($n = 340$)	Italian Sibs ($n = 100$)	Spanish Sibs ($n = 120$)	German Sibs ($n = 120$)	dnPDs ($n = 159$)	CTRs ($n = 109$)	ISNB vs SAS vs UMG <i>p</i>	UMG vs ISNB; UMG vs SAS; ISNB vs SAS	dnPDs vs German Sibs OR (CI)/ β_{conf} (CI)	CTRs vs German Sibs OR (CI)/ β_{conf} (CI)
	Adj. <i>p</i>	Adj. <i>p</i>	Adj. <i>p</i>	Adj. <i>p</i>	Adj. <i>p</i>	Adj. <i>p</i>	Adj. <i>p</i>	Adj. <i>p</i>	Adj. <i>p</i>	
Men ^a	141 (41.5%)	44 (44.0%)	51 (42.5%)	46 (38.6%)	105 (66.0%)	66 (60.6%)	0.688	0.001	3.13 (1.91–5.12)	2.47 (1.45–4.20)
Age (yrs.) ^a	62.13 ± 10.72	63.64 ± 9.64	57.77 ± 11.17	65.23 ± 9.73	65.25 ± 9.70	64.71 ± 6.85	<0.001	0.981	0.03 (–2.11–2.17)	–0.51 (–2.85–1.83)
Age difference with PD Sibs (yrs.) ^b	-1.09 ± 6.46	-3.24 ± 6.63	0.42 ± 6.53	-0.78 ± 5.79	–	–	<0.001	–	–	–
Age at PD onset in PD Sibs (yrs.) ^b	56.21 ± 10.71	58.14 ± 8.78	50.31 ± 10.17	60.32 ± 10.24	–	–	<0.001	–	–	–
Education (yrs.) ^a	11.68 ± 4.35	11.12 ± 4.09	10.47 ± 5.00	13.39 ± 3.21	9.93 ± 2.98	10.11 ± 2.97	<0.001	–	–3.49 (–4.26–2.73)	–3.16 (–3.99–2.33)
BMI (kg/m ²) ^a	26.55 ± 4.28	26.24 ± 4.15	27.33 ± 4.19	26.03 ± 4.40	27.79 ± 4.48	26.69 ± 4.32	0.045	–	1.76 (0.71–2.81)	0.65 (–0.50–1.80)
Comorbidities										
Hypertension	123 (36.3%)	29 (29.0%)	38 (31.7%)	56 (46.7%)	96 (60.4%)	53 (48.6%)	0.012	0.004 ; 0.165; 0.207	1.19 (0.66–2.16)	0.81 (0.43–1.52)
Diabetes	31 (9.3%)	4 (4.0%)	16 (13.3%)	11 (9.6%)	70 (10.7%)	8 (7.3%)	0.058	0.071; 0.091; 0.001	0.98 (0.38–2.52)	0.73 (0.24–2.20)
Dyslipidemia	86 (25.5%)	22 (22.0%)	33 (27.5%)	31 (26.1%)	68 (42.8%)	64 (58.7%)	0.687	0.470; 0.705; 0.168	1.62 (0.89–2.94)	3.00 (1.59–5.64)
Hyperuricemia	19 (5.6%)	4 (4.0%)	7 (5.7%)	8 (6.7%)	13 (8.2%)	4 (3.7%)	0.688	0.119; 0.317; 0.501	0.60 (0.19–1.89)	0.23 (0.05–0.99)
Hypothyroidism	31 (9.1%)	4 (4.0%)	4 (3.3%)	23 (19.2%)	19 (11.9%)	10 (9.2%)	<0.001	0.001 ; 0.341	0.62 (0.26–1.47)	0.45 (0.18–1.18)
Cancer history	27 (7.9%)	7 (7.0%)	5 (4.2%)	15 (12.5%)	17 (10.7%)	9 (8.3%)	0.053	0.464; 0.331; 0.360	0.93 (0.38–2.24)	0.66 (0.24–1.79)

Continuous variables are expressed in mean \pm standard deviation, discrete in number (%). Adjustments have been made for age, sex, education, smoking, and coffee intake. Statistically significant coefficients and *p*-values are reported in bold.

Total Sibs total cohort of siblings of PD patients, Italian Sibs siblings coming from Azienda Unità Sanitaria Locale di Bologna—IRCCS Istituto delle Scienze Neurologiche di Bologna (Italy), Spanish Sibs siblings coming from Servicio Andaluz de Salud (Spain), German Sibs siblings coming from Universitätsmedizin Göttingen (Germany), dnPDs de novo PD patients from DeNoPa cohort, CTRs controls from DeNoPa cohort, Adj. *p* *p*-adjusted for covariates, OR odds ratio, CI 95% confidence interval, β_{conf} coefficient of regression from linear regression, PD Sibs sibling affected with Parkinson's Disease, BMI body mass index.

^aThese variables have not been adjusted.

Table 2. MDS-UPDRS in Siblings and DeNoPa cohorts.

	PROPAG-AGEING Siblings' cohort					DeNoPa cohort		Siblings' comparisons		Comparisons with DeNoPa		
	Total Sibs (n = 340)	Italian Sibs (n = 100)	Spanish Sibs (n = 120)	German Sibs (n = 120)	dnPDs (n = 159)	CTRs (n = 109)	ISNB vs SAS vs UMG		dnPDs vs German Sibs		CTRs vs German Sibs	
							p	Adjusted p (UMG vs ISNB; UMG vs SAS; ISNB vs SAS)	IRR (CI)	Adj. p	IRR (CI)	Adj. p
MDS-UPDRS												
Part I	2 (0–4)	1 (0–2)	2 (0–4)	3 (1–6)	5 (3–10)	2 (1–4)	<0.001	<0.001; <0.001; <0.001	1.51 (1.32–1.71)	<0.001	0.62 (0.53–0.73)	<0.001
Part II	0 (0–0)	0 (0–0)	0 (0–0)	0 (0–2)	8 (5–12)	0 (0–0)	<0.001	<0.001; <0.001; <0.001	7.23 (5.97–8.76)	<0.001	0.16 (0.10–0.26)	<0.001
Part III	0 (0–2)	1 (0–2)	0 (0–1)	1 (0–3.5)	22 (14–31)	0 (0–0)	<0.001	<0.001; 0.016; 0.444	10.54 (9.23–12.03)	<0.001	0.27 (0.21–0.35)	<0.001
Part III without action and postural tremor	0 (0–2)	0 (0–2)	0 (0–0)	1 (0–3)	21 (13–31)	0 (0–0)	<0.001	<0.001; <0.001; 0.072	10.98 (9.56–12.62)	<0.001	0.19 (0.13–0.26)	<0.001
Part IV	0 (0–0)	0 (0–0)	0 (0–0)	0 (0–0)	0 (0–0)	0 (0–0)	0.331	–	–	–	–	–
Total	3 (1–7)	2.5 (1–4)	2 (0–7)	5.5 (3–11)	35 (24–50)	2 (1–5)	<0.001	<0.001; <0.001; <0.001	5.07 (4.69–5.48)	<0.001	0.45 (0.40–0.51)	<0.001
Subtle PD signs												
Part II score > 1	43 (12.65%)	1 (1.0%)	11 (9.2%)	31 (25.8%)	154 (96.9%)	6 (5.5%)	<0.001	<0.001; 0.014; 0.011	66.50 (22.20–199.20)	<0.001	0.10 (0.03–0.33)	<0.001
Part III score > 1	119 (35.0%)	43 (43.0%)	23 (19.2%)	53 (44.2%)	159 (100%)	16 (14.7%)	<0.001	0.764; 0.029; 0.017	–	–	0.29 (0.13–0.69)	0.005
Part III score > 6 without action and postural tremor	15 (4.4%)	1 (1.0%)	2 (1.6%)	12 (10.0%)	150 (94.3%)	0 (0.0%)	0.016	0.009; 0.032; 0.192	298.95 (69.71–1281.95)	<0.001	–	–

Continuous, not normally distributed variables are expressed in median (1st–3rd quartile), discrete in number (%). Adjustments have been made for age, sex, education, smoking, and coffee intake. Statistically significant coefficients and *p*-values are reported in bold. Group acronyms are the same as explained in Table 1; MDS-UPDRS Movement Disorders Society; Unified Parkinson's Disease Rating Scale; Adj. *p* *p*-adjusted for covariates, IRR incidence rate ratio, OR odds ratio, CI 95% confidence interval.

Non-motor evaluation

Symptoms of orthostatic hypotension (OH) were the most frequent (47 Sibs; 13.8%), with a greater prevalence in German Sibs ($p = 0.006$) compared to Italian and Spanish Sibs, followed by constipation (40 Sibs; 11.8%). There was a tendency for more sexual dysfunction and orthostatic hypotension among German Sibs than CTRs ($p = 0.058$, $p = 0.073$, and $p = 0.072$, respectively). Complete autonomic data are presented in Table 3.

Among Sibs, the mean Sniffin' Sticks Screening score was 9.51 ± 2.04 ; 22 Sibs (6.5%) were under the 10th percentile according to age and sex. Olfaction identification testing showed no difference between German Sibs and CTRs; dnPDs presented the worst performances ($p < 0.001$). Complete olfaction data are presented in Table 3.

Eight Sibs (2.4%) presented with anxiety disorder, 36 with depression (10.6%), there were no differences between the three recruiting centers. DnPDs suffered more from depression with a trend for a higher prevalence of anxiety disorders than German Sibs ($p = 0.04$ and 0.061 , respectively); they also used more antidepressants ($p = 0.001$). Detailed results on affective-behavioral evaluation can be found in Table 4.

Sibs obtained an adjusted MoCA mean score of 26.22 ± 3.36 ; 109 Sibs (32.2%) showed abnormal results (score < 26 points). The prevalence of individuals with an abnormal MoCA score was partially comparable among the centers, although the test score was higher in German Sibs (27.04 ± 2.99) compared to ISNB- and Spanish Sibs. German Sibs did not score differently from CTRs. DnPDs were two-fold more cognitively impaired on the MoCA ($p = 0.036$) and presented with lower scores when compared to German Sibs. When cognitive domains were considered in detail, German Sibs scored worse than CTRs in visuospatial/executive [0.42 (CI 0.16–0.69) points, $p = 0.002$] and language [0.43 (CI 0.20–0.65) points, $p < 0.001$] tasks, without being different from dnPDs, and performed better than both groups in abstraction and short-term memory tasks. Specific data on cognition can be found in Table 4.

Sibs scored a median of 2 (0–4) points on the MDS-UPDRS part I and was significantly higher in German Sibs ($p < 0.001$). In addition, German Sibs showed a lower non-motor burden than dnPDs ($p < 0.001$), but higher than CTRs ($p < 0.001$). MDS-UPDRS part I data are shown in Table 2.

Sleep evaluation

One-hundred and forty-seven Sibs (49 German Sibs and 98 Italian Sibs) underwent vPSG. Mean sleep efficiency (SE) was $74.47 \pm 18.48\%$ and significantly higher in Italian Sibs ($p < 0.001$). Italian Sibs also showed a higher proportion of N3 sleep ($p < 0.001$). Three (2.1%) Sibs (2 German Sibs, 1 ISNB-Sib) had vPSG-confirmed RBD. All three RBD positive Sibs were negative on the RBDSQ (score < 5). According to the RBDSQ, 27 (8.0%) Sibs were positive for probable (clinical) RBD (pRBD). Among the 27 pRBD, 18 Sibs were investigated with a vPSG, which excluded RBD in each of them.

vPSG-confirmed RBD was not more prevalent in German Sibs than in CTRs (4.3% vs 1.8%, respectively), whilst it was more frequent in dnPDs (25.3%).

RBD results are shown in Table 4, complete vPSG data can be found in Supplementary Table 3.

Prodromal PD probability

Prodromal PD probability was calculated according to MDS Research Criteria for Prodromal PD¹⁵, in their revised form²⁰. The 300 Sibs over the age of 50 obtained a median prodromal PD probability of 0.75% (0.32–2.19%). One hundred and seventy-three Sibs had a <1% probability of having prodromal PD, 100 Sibs reached a probability between 1 and 10%, and 27 had a

Table 3. Autonomic and olfaction data of siblings and DeNoPa cohorts.

	PROPAG-AGEING Siblings' cohort					DeNoPa cohort		Siblings' comparisons		Comparisons with DeNoPa	
	Total Sibs (n = 340)	Italian Sibs (n = 100)	Spanish Sibs (n = 120)	German Sibs (n = 120)	dnPDs (n = 159)	CTRs (n = 109)	ISNB vs SAS vs UMG UMG vs SAS; ISNB vs SAS)	Adj. p	dnPDs vs German Sibs	Adj. p	CTRs vs German Sibs
							P		OR (CI)/ β_{conf} (CI)		OR (CI)/ β_{conf} (CI)
<i>Autonomic function</i>											
Orthostatic hypotension symptoms	47 (13.8%)	5 (5.0%)	18 (15.0%)	24 (20.0%)	20 (12.9%)	9 (8.3%)	0.005	0.006 ; 0.194; 0.131	0.67 (0.31–1.47)	0.320	0.43 (0.17–1.08)
Constipation symptoms	40 (11.8%)	10 (10.0%)	15 (12.5%)	15 (12.5%)	36 (22.6%)	5 (4.6%)	0.794	0.484; 0.845; 0.647	2.63 (1.18–5.89)	0.018	0.42 (0.14–1.32)
Erectile/sexual symptoms	17 (11.3%)	7 (14.3%)	5 (8.3%)	5 (11.9%)	35 (22.6%)	6 (5.5%)	0.612	0.411; 0.444; 0.832	1.40 (0.44–4.49)	0.571	0.26 (0.06–1.05)
NMS Q26 f's	0.36 ± 1.19	0.46 ± 1.27	0.17 ± 0.64	0.52 ± 1.16	0.80 ± 2.13	0.21 ± 1.26	0.546	0.352; 0.151; 0.630	–0.05 (–0.73–0.63)	0.887	–0.64 (–1.35–0.06)
Sudomotor Symptoms	n = 204	n = 100	n = 61	n = 43	n = 155	n = 109			0.88 (0.34–2.30)	0.800	0.63 (0.23–1.76)
NMS Q30 f's	23 (11.3%)	7 (7.0%)	7 (11.5%)	9 (20.9%)	32 (20.6%)	16 (14.7%)	0.054	0.012 ; 0.117; 3.48	0.19 (–0.74–1.11)	0.691	–0.15 (–1.11–0.81)
Olfaction	0.44 ± 1.60	0.24 ± 1.30	0.40 ± 1.53	0.95 ± 2.10	1.15 ± 2.77	0.72 ± 2.18	0.041	0.011 ; 0.039 ; 0.699			
SSS score	9.51 ± 2.04	9.06 ± 2.35	9.72 ± 1.75	9.68 ± 2.00	5.78 ± 2.89	9.45 ± 1.86	0.090	0.060; 0.483; 0.149	– 3.67 (–4.32–3.01)	< 0.001	–0.08 (–0.78–0.62)
<10th percentile age and sex corrected ^a	22 (6.5%)	9 (9.0%)	8 (6.8%)	5 (4.2%)	74 (46.5%)	6 (5.5%)	0.347	0.236; 0.622; 0.392	21.73 (8.02–58.91)	< 0.001	1.43 (0.41–5.02)

Continuous variables are expressed in mean ± standard deviation, discrete in number (%). Adjustments have been made for age, sex, education, smoking, and coffee intake. Statistically significant coefficients and p-values are reported in bold, tentatively significant ones are in italics.

Group acronyms are the same as explained in Table 1; Adj. p: p-adjusted for covariates, OR odds ratio, CI 95% confidence interval, β_{conf} coefficient of regression from linear regression, NMS Q26 f's frequency × severity score obtained on question no. 26 at the Non-Motor Symptoms Questionnaire, NMS Q30 f's frequency × severity score obtained on question no. 26 at the Non-Motor Symptoms Questionnaire, SSS Sniffin' Sticks Screening.

^aNot statistically re-corrected for age and sex.

probability >10% (Fig. 1a). None of the 4 Sibs with two affected PD siblings had a probability greater than 10%. One sibling (0.33%) exceeded 80% probability (95.9%), fulfilling the criteria for Prodromal PD: he presented vPSG-confirmed RBD, constipation, and MDS-UPDRS III >6. The other two Sibs with confirmed RBD, the greatest prodromal PD risk factor, presented a probability of 40.2% and 36.8%, respectively.

One hundred and twelve German Sibs and 107 CTRs from DeNoPa over the age of 50 were evaluated for prodromal PD probability; family history of PD was not taken into consideration for this comparison. German Sibs presented with a median prodromal PD probability of 0.43% (0.17–1.09%), statistically greater than CTRs [0.215 (CI 0.12–0.45%), $p < 0.001$]. One UMG-Sib and no CTRs fulfilled the criteria for prodromal PD. The distribution of prodromal PD probability values was more heterogeneous in the German Sibs group compared to CTRs (Fig. 1b).

Detailed results on prodromal PD probability are shown in Table 5.

Distribution of prodromal PD markers

One hundred and forty-six out of 340 Sibs (42.9%) presented at least one prodromal PD marker, of whom 104 (30.6%) had only one marker, 29 (8.5%) had 2 markers and 13 (3.8%) had 3 markers. The most frequently associated markers were constipation and depression in 11 Sibs, followed by symptoms of OH-constipation and symptoms of OH-depression (7 Sibs each) (Supplementary Fig. 1, Part A).

Fifty-nine out of 120 (49.2%) German Sibs and 40 out of 109 (36.7%) CTRs presented at least one prodromal PD marker. The most frequently associated markers in German Sibs were constipation and depression (6 siblings) (Supplementary Fig. 1, Part B i), while in CTRs impaired olfaction and depression (3 controls) (Supplementary Fig. 1, Part B ii) were present. No difference was present between German Sibs and CTRs in the number of prodromal PD markers, when correcting for not equally distributed variables (adjusted $p = 0.388$).

Results on prodromal PD markers distribution are shown in Table 5.

DISCUSSION

To the best of our knowledge, this is the largest multi-national PD siblings' study and the first one extensively evaluating motor and NMS and video-polysomnographically-validated RBD in this population^{9,33,34}. In our study, we used a multi-national recruitment design with the inherent advantage of avoiding the gap of specific population characteristics and preventing the limitation of generalizability of the results. As part of our methodological approach, we analyzed both the MDS estimate of prodromal PD probability^{15,20} and considered the distribution of prodromal PD markers.

The main findings of our study are the following:

1. PD siblings showed subtle signs of motor and non-motor impairment, but when comparing German Sibs with CTRs, the differences were either not significant or did not fulfill criteria for clinical relevance, as outlined by Horvath^{37,38}. From the motor point of view, the siblings obtained motor results comparable to non-converters, low-risk individuals¹⁶, and the general elderly population³⁹, also the prevalence of siblings with mild parkinsonian signs was comparable to the general population⁴⁰.
2. Regarding NMS, no relevant differences were found among Sibs from the three centers and between German Sibs and CTRs. German Sibs showed a significant increase of NMS impact on activities of daily living (MDS-UPDRS part I) with

Table 4. Cognitive, affective-behavioral, and RBD data of siblings and DeNoPa cohorts.

	PROPAG-AGEING Siblings' cohort				DeNoPa cohort		Siblings' comparisons		Comparisons with DeNoPa	
	Total Sibs (n = 340)	Italian Sibs (n = 100)	Spanish Sibs (n = 120)	German Sibs (n = 120)	dnpDs (n = 159)	CTRs (n = 109)	dnpDs vs German Sibs		CTRs vs German Sibs	
							OR (CI)/ β_{coef} (CI)	Adj. p	OR (CI)/ β_{coef} (CI)	Adj. p
Cognition		n = 119	n = 98							
MoCA adjusted	26.22 ± 3.36	25.39 ± 2.98	26.10 ± 3.81	27.04 ± 2.99	24.52 ± 3.09	25.95 ± 2.36	<0.001	0.004 ; 0.049 ; 0.311	-1.18 (-1.88--0.47)	0.001
Visuospatial-executive	-	-	-	4.29 ± 1.02	4.18 ± 1.01	4.53 ± 0.69	-	-	0.05 (-0.20-0.31)	0.680
Language	-	-	-	5.41 ± 0.77	5.12 ± 0.81	5.46 ± 0.80	-	-	0.10 (-0.12-0.33)	0.354
Attention, concentration, working memory	-	-	-	5.68 ± 0.74	5.45 ± 0.93	5.71 ± 0.54	-	-	-0.08 (-0.30-0.14)	0.489
Abstraction	-	-	-	1.83 ± 1.96	1.23 ± 1.46	1.29 ± 1.56	-	-	-0.37 (-0.53--0.21)	<0.001
Short-term memory	-	-	-	3.35 ± 1.56	2.00 ± 1.67	2.48 ± 1.57	-	-	-0.93 (-1.37--0.49)	<0.001
Orientation	-	-	-	5.93 ± 0.30	5.94 ± 0.24	5.98 ± 0.14	-	-	0.037 (-0.034-0.109)	0.304
Abnormal MoCA	109 (32.2%)	44 (44.0%)	36 (30.3%)	29 (24.2%)	70 (58.8%)	41 (41.8%)	0.006	0.015 ; 0.200; 0.203	1.97 (1.04-3.70)	0.036
Affective-behavioral										
Anxiety disorder	8 (2.4%)	3 (3.0%)	2 (1.7%)	3 (2.5%)	13 (8.2%)	3 (2.8%)	0.803	0.427; 0.844; 0.228	4.34 (0.94-20.1)	0.061
Depression	36 (10.6%)	7 (7.0%)	13 (10.8%)	16 (13.3%)	35 (22.0%)	17 (15.6%)	0.313	0.135; 0.392; 0.699	2.30 (1.04-5.11)	0.040
RBD										
Clinical (RBD) - Score	1.71 ± 1.85	1.94 ± 1.82	1.26 ± 1.78	1.98 ± 1.88	3.65 ± 2.81	2.38 ± 2.23	<0.001	0.425 ; 0.002 ; 0.005	1.36 (0.70-2.02)	<0.001
Positive	27 (8.0%)	9 (9.0%)	6 (5.0%)	12 (10.1%)	43 (28.7%)	17 (16.0%)	0.314	0.245; 0.030 ; 0.213	2.85 (1.24-6.57)	0.014
vPSG-confirmed	n = 147	n = 98	-	n = 49	n = 159	n = 109	0.687	0.882	8.93 (1.83-43.53)	0.007
	3 (2.0%)	1 (1.0%)	-	2 (4.3%)	40 (25.3%)	2 (1.8%)			0.55 (0.07-4.37)	0.576

Continuous variables are expressed in mean ± standard deviation, discrete in number (%). Adjustments have been made for age, sex, education, smoking, and coffee intake. Statistically significant coefficients and p-values are reported in bold, tentatively significant ones are in italics. Group acronyms are the same as explained in Table 1; Adj: p-adjusted for covariates, OR odds ratio, CI 95% confidence interval, β_{coef} coefficient of regression from linear regression, MoCA Montreal Cognitive Assessment, RBD REM Sleep Behavior Disorder, RBD SQ REM Sleep Behavior Disorder Screening Questionnaire, vPSG video-polysomnography.

^aNot statistically re-corrected for age and sex.




Fig. 1 Prodromal PD probability of Siblings and DeNoPa cohorts. **a** Density distribution of prodromal PD probability. **b** Density distribution of prodromal PD probability in German Sibs and CTRs.

respect to CTRs, even if they differed by only 1 point. Our data agree with one out of the only three studies evaluating NMS in PD relatives, which did not find any difference with healthy controls⁹. The other two studies found an increased prevalence of anxiety and depression in PD relatives^{33,34}. These incongruences could be explained by the different cohorts considered (first-degree relatives in general vs siblings) and by the different methodologies used to assess depression and anxiety (questionnaires and database records vs medical history). Indeed, our results show that reactive anxiety and depression, possibly related to the fear of developing PD, is not an issue in our population.

3. The prevalence of participants with an abnormal MoCA score was partially comparable among the centers. German Sibs did not perform differently from CTRs according to MoCA total score. However, German Sibs performed significantly worse than CTRs in visuospatial-executive functions and language, becoming similar to dnPDs in these subtests. Occurrence and characteristics of cognitive decline before PD onset are poorly understood⁴¹. To date, just three prospective population studies^{18,42,43} have demonstrated how lower scores in executive, visuospatial, and language functions could increase the risk of developing PD, while one study found lower cognitive performances to be connected with a higher probability of prodromal PD⁴⁴. Only one study considered cognition in PD relatives, without evaluation of specific cognitive domains, finding no differences with controls³³.
4. PD siblings did not show a higher prevalence of vPSG-validated RBD compared to the general population. Indeed,

of the 147 Sibs evaluated by vPSG, only 3 Sibs had confirmed RBD. Using RBDSQ, Liu et al. previously reported an RBD prevalence in PD Sibs of 13.3% against 3.6% in controls³³, which we were not able to confirm in our cohorts. However, in our cohort, we did not find concordance between vPSG and RBDSQ, and it is possible that in previous studies the use of RBDSQ overestimated the prevalence of RBD in PD sibs as the RBDSQ has not been validated in the general population and its specificity is generally low^{45–47}.

5. Although the Sibs cohort is expected to be at higher risk²⁹, only one Sib out 300 met the criteria for probable prodromal PD; this prevalence is not higher than the findings in a population cohort of otherwise healthy elderly individuals²⁷. In our settings, the estimate of prodromal PD probability fails to identify PD siblings as a cohort at high risk as a whole and, therefore, the criteria of prodromal PD, which are mainly driven by the presence of RBD, do not show a higher risk of PD in our cohort. Whether this result depends on the validity or better on the sensitivity of the prodromal PD criteria or if the risk is actually not elevated in PD siblings cannot reliably be answered by the current data.
6. PD siblings showed a heterogeneous distribution of prodromal PD probability when using the MDS criteria for prodromal PD, as highlighted by the comparison between German Sibs and German CTRs. Twenty-seven of 300 Sibs had a probability of more than 10% of having prodromal PD and 42 of 340 Sibs presented at least two PD markers, hence, at-risk subjects were few but highly impacted⁴⁸. In fact, by evaluating the distribution of score values and combined markers a subgroup of higher-risk individuals emerged, which disappears, if the specific marker of RBD is added and calculated.

Collectively, these results suggest on one hand that a reappraisal of currently available tools is needed, as they are only in part able to grasp the higher risk of PD siblings as reported by epidemiological data. Strong markers from additional clinical, biochemical (such as abnormal synuclein in the cerebrospinal fluid or in tissues), and molecular (e.g., polymorphisms in known at-risk loci) parameters should be investigated to increase their sensitivity and help in disentangling heterogeneity as an intrinsic feature of PD neurodegeneration process. In parallel with PD subtypes, heterogeneity can reside also in the prodromal state and without broadening our search we could miss many prodromal PD patients. On the other hand, our results did show that prodromal symptoms are very uncommon in siblings, which could suggest that the low sibling risk is not a question of partial penetrance, but that siblings despite being more epidemiologically at risk of developing PD would not stall at a prodromal stage before some of them actually manifested the disease. Indeed, recent evidence showed borderline sensitivity when applying prodromal PD to the incident or longitudinal not enriched cohorts^{49,50}.

Our study has several limitations. First, data of a de novo PD cohort were only available for the German center and we, therefore, decided to compare only German Sibs with de novo PD and controls, thus reducing numbers and statistical power. Second, genetic tests for known PD variants were not carried out at this stage. Third, apart from sleep with vPSG and odor identification impairment, other NMS were evaluated using patient reports and questionnaires, without instrumental or objective measurements, especially for strong prodromal NMS such as orthostatic hypotension. No interrater testing or training was performed prior to the study in the three sites, therefore interrater variabilities could account for the differences in ratings. The sleep studies are only partially comparable, as there are inherent differences between the compared lab-based vPSG in

Table 5. Prodromal PD Probability and Markers in siblings and DeNoPa cohorts.

	PROPAG-AGEING Siblings' cohort				DeNoPa cohort	Comparisons with DeNoPa	
	Total Sibs	Italian Sibs	Spanish Sibs	German Sibs	CTRs	CTRs vs German Sibs	
	<i>n</i> = 300	<i>n</i> = 92	<i>n</i> = 96	<i>n</i> = 112	<i>n</i> = 107	IRR (CI)/ β_{coef} (CI)	Adj. <i>p</i>
<i>Prodromal PD calculation</i>							
Prodromal PD probability (%)	0.75 (0.32–2.19)	0.54 (0.27–1.27)	0.80 (0.28–2.32)	1.07 (0.43–2.69)	–	–	–
Log ₁₀ (probability)	–0.04 ± 0.66	–0.20 ± 0.62	–0.06 ± 0.62	0.10 ± 0.70	–	–	–
Prodromal PD probability without fam. his. (%)	0.30 (0.13–0.91)	0.22 (0.11–0.57)	0.32 (0.11–0.94)	0.43 (0.17–1.09)	0.21 (0.12–0.45)	0.64 (0.51–0.82)	<0.001
Log ₁₀ (probability)	–0.40 ± 0.86	–0.49 ± 1.16	–0.45 ± 0.64	–0.28 ± 0.73	–0.58 ± 0.63	–0.22 (–0.41–0.03)	0.025
Prodromal PD positive	1 (0.33%)	0 (0.0%)	0 (0.0%)	1 (0.9%)	0 (0.0%)	–	–
Prodromal PD markers	<i>n</i> = 340	<i>n</i> = 100	<i>n</i> = 120	<i>n</i> = 120	<i>n</i> = 109	OR (CI)	<i>p</i>
# of markers	0 (0–1)	0 (0–1)	0 (0–1)	0 (0–1)	0 (0–1)	0.75 (0.39–1.43)	0.388
≥2 markers	42 (12.3%)	8 (8%)	14 (11.7%)	20 (16.7%)	11 (10.1%)	0.53 (0.18–1.55)	0.247

Continuous, not normally distributed variables and ordinal variables are expressed in median (1st–3rd quartile), continuous, normally distributed variables are expressed in mean ± standard deviation, discrete in number (%). Adjustments have been made for age, sex, education, smoking, and coffee intake. Statistically significant coefficients and *p*-values are reported in bold.

Group acronyms are the same as explained in Table 1; Adj. *p* *p*-adjusted for covariates, IRR incidence rate ratio, CI 95% confidence interval, β_{coef} coefficient of regression from linear regression, Prodromal PD probability without fam. his. prodromal PD probability computed without considering the history of PD in first-degree relatives, Log₁₀(probability) base 10 logarithm of prodromal PD probability.

Germany (UMG) and the home-based vPSG (ISNB), although both centers are experienced in PSG RBD diagnosis, while no vPSG data were included from SAS.

On the other hand, our study described motor and non-motor clinical and video-polysomnographic features in the largest PD sibling cohort up to date, using a multi-center approach, thus excluding the risk of clustered genetic and environmental risk factors related to the geographical context, especially in enclosed communities³⁰. Furthermore, PD patients and siblings were not related but originated from different families. Indeed, the previous studies^{9,33,34} showed strong similarities between PD patients and siblings due to familial clustering, affecting not only PD-related markers but also possibly biasing features.

Our study indicates that siblings have a heterogeneous distribution of motor and non-motor signs. Additional clinical, biochemical, and molecular parameters not currently included in MDS criteria, and a focalized analysis of the more at-risk subjects, should pave the way of future analyses within the project. Finally, a prospective follow-up of an expanded collaborative international cohort can represent the right path to disentangle the complex interplay between genetic and environmental factors, characterizing the neurodegenerative and heterogeneous process¹⁴ of Parkinson's Disease.

METHODS

Design

We report the description of the PPG siblings cohort (Sibs) multicentrically recruited over 29 months between September 2016 and January 2019 by three PPG partners: Azienda Unità Sanitaria Locale di Bologna—IRCCS Istituto delle Scienze Neurologiche di Bologna (ISNB, Italy), Servicio Andaluz de Salud (SAS, Spain) and Paracelsus-Elena Hospital, Kassel as part of Universitätsmedizin Göttingen (UMG-GOE, Germany). Sibs from Bologna and Kassel underwent video-polysomnography. To account for population-specific effects we subsequently compared sibling data from UMG-GOE (German-Sibs) with the baseline data of de novo PD patients (dnPDs) and controls (CTRs) from the DeNoPa cohort from the same center³⁶ (Fig. 2).

Study participants

Siblings of patients with a diagnosis of idiopathic PD according to the International Diagnostic Criteria (UK Brain Bank Criteria⁵¹), were recruited. The diagnoses of the affected PD patients were verified in each recruiting

center by neurologists experienced in movement disorders, all belonging to the PROPAG-AGEING Consortium. Participants had to be over 18 years of age and could not have any active known/treated condition of the central nervous system (e.g., Alzheimer's disease, vascular encephalopathies, multiple sclerosis) including PD; data on dnPDs and CTRs were retrieved from DeNoPa database³⁶. DeNoPa is a large single-center cohort of early PD patients recruited at Paracelsus-Elena Hospital, Kassel including frequency-matched healthy controls. DeNoPa's subjects evaluation includes motor signs, NMS, and a combination of diagnostic tests including olfactory testing, transcranial sonography of substantia nigra, and polysomnography (PSG)³⁶.

Investigations

Each recruited sibling received a full clinical evaluation including complete medical history, accounting for both comorbidities and medication, and a neurological examination performed by a neurologist experienced in movement disorder assessment. Motor symptoms were quantitatively assessed using the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III, while the impact on activities of daily living and NMS was assessed by the MDS-UPDRS parts II and I⁵². NMS were evaluated by means of validated questionnaires, such as the Non-Motor Symptoms Questionnaire (NMSQ—questions 26 and 30)⁵³, the Rome III Diagnostic Criteria for Functional Constipation^{54,55}, the Montreal Cognitive Assessment (MoCA)⁵⁶ and the REM sleep behavior disorder screening questionnaire (RBDSQ)⁴⁶. We also objectively assessed olfactory function using Sniffin' Sticks Screening⁵⁷, obtained selected laboratory and blood parameters (ISNB and UMG-GOE only), and carried out a whole night video-polysomnography (vPSG) in ISNB (at home) and UMG-GOE (in the sleep laboratory) recruited siblings. ISNB home-based vPSG was performed by means of Xtek Trex HD Video Ambulatory system and included three monopolar electroencephalogram channels (as recommended by the American Academy of Sleep Medicine's Manual for the Scoring of Sleep and Associated Events⁵⁸), electrocardiogram (EKG), electrooculogram (EOG), chin and limbs EMG (bilateral extensor carpi and tibialis anterior muscles), and toraco-abdominal respirogram. UMG-GOE lab-based vPSG was performed applying cardiorespiratory PSG and including bilateral monopolar central EEG with 2 channels, EOG, chin and bilateral tibialis anterior surface EMG, airflow registration, tracheal sound registration by microphone, thoracic and abdominal belts to measure respiratory movements, EKG, and oximetry. All patients were documented with an infrared video recording synchronized to the PSG. Further methodological details are described as published elsewhere⁵⁹.




Fig. 2 Study tree of the compared cohorts. Siblings were multicentrically recruited in Italy, Spain and Germany, German siblings were then compared with de novo PD patients and controls from the DeNoPa German cohort.

Computation of prodromal PD probability and evaluation of prodromal PD markers

Prodromal PD probability for Sibs over the age of 50 was computed according to the revised MDS Research Criteria²⁰, which also outlined the prodromal PD markers considered for evaluation. Life risk and prodromal markers were evaluated and accounted for each participant, independently of their age. Subsequent prodromal PD probability calculation taking into account prior probability was computed for those over the age of 50 (prior probability estimates are not available in the literature for younger individuals). Risk scoring was computed as defined in refs. ^{15,20}.

Risk markers were evaluated as follows:

- Sex: biological sex was considered for the purpose. No cases of hermaphroditism or pseudohermaphroditism were present in our cohorts.
- Pesticide and solvent exposure: data not systematically available (NsA) in our cohort and therefore not computed.
- Non-use of caffeine: evaluated as defined in refs. ^{15,20}.
- Smoking: evaluated as defined in refs. ^{15,20}.
- First-degree relative with PD: this risk marker, positive for every sibling in our cohort, was evaluated in the first computation of prodromal PD probability, while it was not taken into account in the comparison between German siblings and healthy controls, to exclude obvious biasing in the calculation. Known gene mutation and polygenic risk scores were not taken into account.
- Substantia nigra hyperechogenicity: NsA data.
- Diabetes mellitus type II: retrieved from accurate medical history.
- Physical inactivity: NsA data.
- Low plasma urate in men: evaluated as defined in ref. ²⁰.

Prodromal markers were evaluated as follows:

- REM sleep behavior disorder (RBD): evaluated as defined in refs. ^{15,20}. However, when the prodromal markers were evaluated for their distribution rather than for the calculation of prodromal PD probability, only video-polysomnographically validated RBD was considered as positive RBD, to guarantee a homogeneous methodological approach.
- Nuclear medicine dopaminergic imaging: NsA data.
- Subthreshold parkinsonism: MDS-UPDRS-III >6 excluding postural and action tremor evaluation was considered.
- Olfactory loss: available sex and age correction, provided by the manufacturer, for olfactory identification testing was adopted. In order to maintain a conservative approach (to prevent overestimation of prodromal markers), only individuals under the 10th percentile according to age and sex were considered as having an objective olfactory dysfunction.
- Constipation: individuals fulfilling Rome III Diagnostic Criteria for Functional Constipation (thus excluding primarily gastrointestinal causes) were considered positive for this marker^{54,55}.
- Excessive daytime somnolence: individuals with a score ≥ 3 on MDS-UPDRS question 1.8, thus responding positively to the following statement: "I sometimes fall asleep when I should not. For example, while eating or talking with other people."

- Neurogenic orthostatic hypotension (OH): NsA data.
- Symptomatic OH: symptoms of OH were evaluated using a semi-structured clinical interview based on either Non-Motor Symptoms Questionnaire or MDS-UPDRS question 1.12.
- Erectile dysfunction in men: erectile dysfunction in men was evaluated using a semi-structured clinical interview based on Non-Motor Symptoms Questionnaire.
- Urinary dysfunction: individuals with a score ≥ 3 at MDS-UPDRS question 1.10, thus responding positively to the following statement: "Urine (control) problems cause a lot of difficulties with my daily activities, including urine accidents."
- Depression (\pm anxiety): individuals were considered positive for depression (and/or anxiety) only when actual disorders, requiring pharmacological treatment and/or psychological assistance, were reported during the clinical interview.
- Global cognitive deficit: cognition was evaluated using the Montreal Cognitive Assessment (MoCA) in our cohort, which presented several issues of cutoff identification when individuals from different nationalities needed to be compared. Therefore, in order to maintain a conservative approach, MoCA score distribution was computed for each subgroup and nationality, individuals below 2 standard deviations were selected as cognitively impaired for prodromal marker selection. It should be noted that our approach is more conservative than the original methodology used by Heinzel et al. to compute the Global cognitive deficit risk score of 1.8, which was derived from studies using a cutoff of only 1 standard deviation²⁰.

Standard protocol approvals, registrations, and patient consents

We conducted the study according to the Declaration of Helsinki and all participants provided informed written consent. The study was approved by the local ethics committees of each recruiting PPG partner (UMG-GOE ethics committee no. of approval 19/5/16 of August 2016, ISNB ethics committee no. of approval 16018 of May 2016, SAS ethical committee no. of approval 2014/PI173 of September 2016).

Database and statistical analysis

A designated online database was created for the study and collected demographic and laboratory data, clinically relevant comorbidities, and questionnaire results. All continuous normally distributed data were expressed as means and standard deviations (SD), while not normally distributed data were expressed as medians and interquartile ranges (IQR); the categorical data were expressed as absolute frequency and percentages (%).

Chi-squared, one-way analysis of variance (ANOVA) or Kruskal-Wallis test were used to investigate the differences between groups (German Sibs and DeNoPa's dnPDs and CTRs) and PD siblings grouped by enrollment center (UMG-GOE, ISNB, SAS) and the demographic and lifestyle variables, comorbidities, medications, MDS-UPDRS parameters, NMS, blood tests, and macrostructure sleep data.

Multivariate logistic regression models, multivariate linear regression models, and multivariate Poisson regression models were used to evaluate

the differences between groups and variables described above, adjusted for the following confounding variables of age, sex, years of education, smoking (cigarettes per day), and coffee intake (cups per day). The results were presented as odds ratios (OR) (95% confidence interval—CI) or β coefficient (95% CI) or incidence rate ratio (IRR) (95% CI).

Statistical analysis was performed using SPSS Statistics version 21 (IBM, Armonk, NY, USA) and Stata SE version 14.2 (StataCorp LLC, Texas, USA).

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

DATA AVAILABILITY

Anonymized data and metadata will be shared by request from any qualified investigator.

Received: 6 March 2021; Accepted: 9 July 2021;

Published online: 07 September 2021

REFERENCES

- Abbas, M. M., Xu, Z. & Tan, L. C. S. Epidemiology of Parkinson's Disease—East versus West. *Mov. Disord. Clin. Pract.* **5**, 14–28 (2018).
- Marras, C. et al. Prevalence of Parkinson's disease across North America. *NPJ Parkinsons Dis.* **4**, 21 (2018).
- Capriotti, T. & Terzakis, K. Parkinson disease. *Home Healthc. Now* **34**, 300–307 (2016).
- Espay, A. J. et al. Disease modification and biomarker development in Parkinson disease: revision or reconstruction? *Neurology* **94**, 481–494 (2020).
- Brás, J., Guerreiro, R. & Hardy, J. Snapshot: genetics of Parkinson's disease. *Cell* **160**, 570–570.e571 (2015).
- Nalls, M. A. et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet Neurol.* **18**, 1091–1102 (2019).
- Rodriguez, M., Rodriguez-Sabate, C., Morales, I., Sanchez, A. & Sabate, M. Parkinson's disease as a result of aging. *Aging Cell* **14**, 293–308 (2015).
- Stankovic, I. et al. Longitudinal assessment of autonomic dysfunction in early Parkinson's disease. *Parkinson. Relat. Disord.* **66**, 74–79 (2019).
- Baig, F. et al. Delineating nonmotor symptoms in early Parkinson's disease and first-degree relatives. *Mov. Disord.* **30**, 1759–1766 (2015).
- Dujardin, K. et al. Apathy in untreated early-stage Parkinson disease: relationship with other non-motor symptoms. *Mov. Disord.* **29**, 1796–1801 (2014).
- Schapira, A. H. V., Chaudhuri, K. R. & Jenner, P. Non-motor features of Parkinson disease. *Nat. Rev. Neurosci.* **18**, 435–450 (2017).
- Durcan, R. et al. Prevalence and duration of non-motor symptoms in prodromal Parkinson's disease. *Eur J Neurol* **26**, 979–985 (2019).
- Schrag, A. et al. Heterogeneity in progression of prodromal features in Parkinson's disease. *Parkinson. Relat. Disord.* **64**, 275–279 (2019).
- Postuma, R. B. & Berg, D. Prodromal Parkinson's disease: the decade past, the decade to come. *Mov. Disord.* <https://doi.org/10.1002/mds.27670> (2019).
- Berg, D. et al. MDS research criteria for prodromal Parkinson's disease. *Mov. Disord.* **30**, 1600–1611 (2015).
- Berg, D. et al. The PRIPS study: screening battery for subjects at risk for Parkinson's disease. *Eur. J. Neurol.* **20**, 102–108 (2013).
- Mahlknecht, P. et al. Performance of the Movement Disorders Society criteria for prodromal Parkinson's disease: a population-based 10-year study. *Mov. Disord.* **33**, 405–413 (2018).
- Ross, G. W., Abbott, R. D., Petrovitch, H., Tanner, C. M. & White, L. R. Pre-motor features of Parkinson's disease: the Honolulu-Asia Aging Study experience. *Parkinson. Relat. Disord.* **18**(Suppl 1), S199–202 (2012).
- Noyce, A. J. et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. *Ann. Neurol.* **72**, 893–901 (2012).
- Heinzel, S. et al. Update of the MDS research criteria for prodromal Parkinson's disease. *Mov. Disord.* <https://doi.org/10.1002/mds.27802> (2019).
- Gustafsson, H., Nordström, A. & Nordström, P. Depression and subsequent risk of Parkinson disease: a nationwide cohort study. *Neurology* **84**, 2422–2429 (2015).
- Ross, G. W. et al. Association of olfactory dysfunction with risk for future Parkinson's disease. *Ann. Neurol.* **63**, 167–173 (2008).
- Marrero-González, P. et al. Prodromal Parkinson disease in patients with idiopathic hyposmia. *J. Neurol.* **267**, 3673–3682 (2020).
- Stirpe, P., Hoffman, M., Badiali, D. & Colosimo, C. Constipation: an emerging risk factor for Parkinson's disease? *Eur. J. Neurol.* **23**, 1606–1613 (2016).
- Moscovich, M. et al. How specific are non-motor symptoms in the prodrome of Parkinson's disease compared to other movement disorders? *Parkinson. Relat. Disord.* **81**, 213–218 (2020).
- Postuma, R. B., Lang, A. E., Gagnon, J. F., Pelletier, A. & Montplaisir, J. Y. How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. *Brain* **135**, 1860–1870 (2012).
- Mahlknecht, P. et al. Prodromal Parkinson's disease as defined per MDS research criteria in the general elderly community. *Mov. Disord.* **31**, 1405–1408 (2016).
- Rocca, W. A. et al. Familial aggregation of Parkinson's disease: The Mayo Clinic family study. *Ann. Neurol.* **56**, 495–502 (2004).
- Thacker, E. L. & Ascherio, A. Familial aggregation of Parkinson's disease: a meta-analysis. *Mov. Disord.* **23**, 1174–1183 (2008).
- Petersen, M. S., Bech, S., Nosova, E., Aasly, J. & Farrer, M. J. Familial aggregation of Parkinson's disease in the Faroe Islands. *Mov. Disord.* **30**, 538–544 (2015).
- Barrett, M. J., Hac, N. E., Yan, G., Harrison, M. B. & Wooten, G. F. Relationship of age of onset and family history in Parkinson disease. *Mov. Disord.* **30**, 733–735 (2015).
- Liu, B., Chen, H., Fang, F., Tillander, A. & Wirdefeldt, K. Early-life factors and risk of Parkinson's disease: A Register-Based Cohort Study. *PLoS ONE* **11**, e0152841 (2016).
- Liu, J. B. et al. Investigation of non-motor symptoms in first-degree relatives of patients with Parkinson's disease. *Parkinson. Relat. Disord.* **52**, 62–68 (2018).
- Arabia, G. et al. Increased risk of depressive and anxiety disorders in relatives of patients with Parkinson disease. *Arch. Gen. Psychiatry* **64**, 1385–1392 (2007).
- Pirazzini, C. et al. A Geroscience approach for Parkinson's Disease: conceptual framework and design of PROPAG-AGEING project. *Mech. Ageing Dev.* 111426, <https://doi.org/10.1016/j.mad.2020.111426> (2020).
- Mollenhauer, B. et al. Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. *Neurology* **81**, 1226–1234 (2013).
- Horvath, K. et al. Minimal clinically important difference on the Motor Examination part of MDS-UPDRS. *Parkinson. Relat. Disord.* **21**, 1421–1426 (2015).
- Horvath, K. et al. Minimal clinically important differences for the experiences of daily living parts of movement disorder society-sponsored unified Parkinson's disease rating scale. *Mov. Disord.* **32**, 789–793 (2017).
- Keezer, M. R., Wolfson, C. & Postuma, R. B. Age, gender, comorbidity, and the MDS-UPDRS: Results from a Population-Based Study. *Neuroepidemiology* **46**, 222–227 (2016).
- Noyce, A. J. et al. Subtle motor disturbances in PREDICT-PD participants. *J. Neurol. Neurosurg. Psychiatry* **88**, 212–217 (2017).
- Fengler, S. et al. Cognitive changes in prodromal Parkinson's disease: a review. *Mov. Disord.* **32**, 1655–1666 (2017).
- Pausch, C. et al. Neuropsychological impairment in prodromal Parkinson's disease. *J. Neurol. Sci.* **371**, 117–120 (2016).
- Darweesh, S. K. L. et al. Association between poor cognitive functioning and risk of incident Parkinsonism: The Rotterdam Study. *JAMA Neurol.* **74**, 1431–1438 (2017).
- Bougea, A. et al. Higher probability of prodromal Parkinson disease is related to lower cognitive performance. *Neurology* **92**, e2261–e2272 (2019).
- Halsband, C., Zapf, A., Sixel-Doring, F., Trenkwalder, C. & Mollenhauer, B. The REM sleep behavior disorder screening questionnaire is not valid in de novo Parkinson's disease. *Mov. Disord. Clin. Pract.* **5**, 171–176 (2018).
- Stiasny-Kolster, K. et al. The REM sleep behavior disorder screening questionnaire—a new diagnostic instrument. *Mov. Disord.* **22**, 2386–2393 (2007).
- Stefani, A. et al. Consistency of “Probable RBD” diagnosis with the RBD screening questionnaire: A Follow-up Study. *Mov. Disord. Clin. Pract.* **4**, 403–405 (2017).
- Gaenslen, A. et al. Prodromal features for Parkinson's disease—baseline data from the TREND study. *Eur. J. Neurol.* **21**, 766–772 (2014).
- Giagkou, N. et al. A prospective validation of the updated movement disorders society research criteria for prodromal Parkinson's disease. *Mov. Disord.* **35**, 1802–1809 (2020).
- Pilotto, A. et al. Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts. *Mov. Disord.* **32**, 1025–1034 (2017).
- Hughes, A. J., Daniel, S. E., Blankson, S. & Lees, A. J. A clinicopathologic study of 100 cases of Parkinson's disease. *Arch. Neurol.* **50**, 140–148 (1993).
- Goetz, C. G. et al. Movement disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. *Mov. Disord.* **23**, 2129–2170 (2008).
- Chaudhuri, K. R. et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. *Mov. Disord.* **21**, 916–923 (2006).

54. Evatt, M. L. et al. Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation-critique and recommendations by movement disorders task force on rating scales for Parkinson's disease. *Mov. Disord.* **24**, 635–646 (2009).
55. Longstreth, G. F. et al. Functional bowel disorders. *Gastroenterology* **130**, 1480–1491 (2006).
56. Nasreddine, Z. S. et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J. Am. Geriatr. Soc.* **53**, 695–699 (2005).
57. Stuck, B. A. et al. Position paper "Chemorensory testing for expert opinion in smell disorders". *Laryngorhinootologie* **93**, 327–329 (2014).
58. Berry, R. et al. *The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications, Version 2.6* (American Academy of Sleep Medicine, Darien, IL, 2020).
59. Sixel-Döring, F., Trautmann, E., Mollenhauer, B. & Trenkwalder, C. Associated factors for REM sleep behavior disorder in Parkinson disease. *Neurology* **77**, 1048–1054 (2011).

ACKNOWLEDGEMENTS

This project has received funding from the European Union's Horizon 2020 research and innovation program Propag-Ageing under grant agreement no. 634821. We express gratitude to Anne-Marie Williams (University Medical Center Göttingen, Göttingen, Germany) and Cecilia Baroncini (IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy) who provided expert editorial and translation assistance.

AUTHOR CONTRIBUTIONS

L.B., S.S., and S.J. contributed equally to the work. P.M., C.T., and F.P. share the last co-authorship. L.B. drafted and revised the manuscript for intellectual content; had a major role in the acquisition of data; analyzed and interpreted the data; S.S. drafted and revised the manuscript for intellectual content; had a major role in the acquisition of data; analyzed and interpreted the data; S.J. drafted and revised the manuscript for intellectual content; had a major role in the acquisition of data; analyzed and interpreted the data; S.R.S. interpreted the data; revised the manuscript for intellectual content. L.S. had a major role in the acquisition of data; interpreted the data; P.G.-G. had a major role in the acquisition of data; C.H. revised the manuscript for intellectual content; had a major role in the acquisition of data; interpreted the data; G.C.-B. designed and conceptualized the study; interpreted the data; A.D.A.-G. had a major role in the acquisition of data; F.S.-D. analyzed and interpreted the data; C.Z. analyzed the data; C.P. designed and conceptualized the study; P.G. designed and conceptualized the study; interpreted the data; M.G.B. revised the manuscript for intellectual content; designed and conceptualized the study; K.P.B. designed and conceptualized the study; interpreted the data; P.C. designed and conceptualized the study; interpreted the data; B.M. had a major role in the acquisition of data; designed and conceptualized the study; interpreted the data; C.F. revised the manuscript for intellectual content; designed and conceptualized the study; interpreted the

data; P.M. had a major role in the acquisition of data; designed and conceptualized study; interpreted the data; C.T. revised the manuscript for intellectual content; designed and conceptualized study; interpreted the data; F.P. revised the manuscript for intellectual content; designed and conceptualized study; analyzed and interpreted the data.

COMPETING INTERESTS

L.B., S.S., S.J., S.R.S., C.H., and A.A.-G. have received salaries from the EU Horizon 2020 research and innovation program under Grant Agreement No. 634821. K.P.B., P.M., and F.P. have received research funds from the EU Horizon 2020 research and innovation program under Grant Agreement No. 634821. B.M. has received research funds from the European Union. C.T. has received research funds from the Michael J. Fox Foundation and the EU Horizon 2020 research and innovation program under Grant Agreement No. 634821. L.S., P.G.-G., G.C.-B., F.S.-D., C.Z., C.P., P.G., M.G.B., P.C., and C.F. declares no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41531-021-00219-1>.

Correspondence and requests for materials should be addressed to F.P.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021

PROPAG-AGEING CONSORTIUM

Henry Houlden⁶, Pietro Liò¹², Claudio Luchinat²⁰, Massimo Delledonne^{14,22}, Kevin Mills¹³, Nancy L. Pedersen¹⁹, Tiago Azevedo¹², Anna Bartoletti-Stella⁷, Marta Bonilla-Toribio^{4,5}, Dolores Buiza-Rueda^{4,5}, Sabina Capellari^{1,7}, Mario Carrión-Claro^{4,5}, Robert Clayton¹³, Alessandra Dal Molin¹⁴, Giovanna Maria Dimitri¹², Ivan Doykov¹³, Cristina Giuliani^{17,18}, Sara Hägg¹⁹, Jenny Hällqvist¹³, Wendy Heywood¹³, Ismael Huertas^{4,5}, Juulia Jylhävä¹⁹, Miguel A. Labrador-Espinosa^{4,5}, Cristina Licari²⁰, Daniel Macias^{4,5}, Francesca Magrinelli^{5,22}, Juan Francisco Martín Rodríguez^{4,5}, Maria Giovanna Maturò²³, Giacomo Mengozzi⁷, Gaia Meoni²⁴, Maddalena Milazzo¹⁰, Christine Nardini²⁵, Nancy L. Pedersen¹⁹, Maria Teresa Perinán-Tocino^{4,5}, Francesco Ravaoli¹⁰, Claudia Sala¹⁰, Simeon Spasov¹², Cristina Tejera-Parrado^{4,5}, Leonardo Tenori²⁰, Turano Paola²⁰, Dylan Williams¹⁹, Luciano Xumerle¹⁴, Elisa Zago¹⁴, Marcella Brolì⁷, Dolores Buiza-Rueda^{4,5}, Patrizia De Massis¹⁵, Rocio Escuela-Martin^{4,5}, Giovanni Fabbri¹⁶, Anna Gabellini⁷, Pietro Guaraldi⁷, Henry Houlden⁶, Stefania Macri²¹, Stefania Alessandra Nasseti⁷, Cesa Lorella Maria Scaglione⁷, Franco Valzania²⁶, Cilea Rosaria⁷, Francesco Mignani⁷, Rosario Vigo Ortega^{4,5}, Claudia Boninsegna⁷ and Silvia De Luca⁷

¹²University of Cambridge, Cambridge, United Kingdom. ¹³UCL Institute of Child Health Library, London, United Kingdom. ¹⁴Personal Genomics Srl, Verona, Italy. ¹⁵S. Maria della Scaletta Hospital, Imola, Italy. ¹⁶Azienda Unità Sanitaria Locale di Bologna, Bologna, Italy. ¹⁷University of Bologna, Bologna, Italy. ¹⁸University of Oxford, Oxford, United Kingdom. ¹⁹Karolinska Institutet, Stockholm, Sweden. ²⁰CERM, University of Florence, Florence, Italy. ²¹Casa di cura Villa Baruzziana, Bologna, Italy. ²²University of Verona, Verona, Italy. ²³University of L'Aquila, L'Aquila, Italy. ²⁴Giotto Biotech srl, Florence, Italy. ²⁵Consiglio Nazionale delle Ricerche, Roma, Italia. ²⁶Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy. A list of members and their affiliations appears in the Supplementary Information.